-
MJFF Guest Blogger: Alejandro Carcano; “From Buenos Aires to New York: 12,000 Kilometers to Prove You Can Live Fully with Parkinson’s”
February 3, 2026
… on the streets of New York City. I have never been able to imagine my life without a bicycle. For as long as I can … philosophy. Running a bike shop, I taught people not just how to pedal, but how to embrace cycling as a way of life: … intentional. At twenty kilometers an hour, the landscape becomes your friend—every road offers a new perspective. I …
-
2019 Parkinson’s Advocacy Awards Presented to Community Members
September 19, 2019
… From L to R: Dan Lewis, Christiana Evers (Parkinson’s Foundation), … were recognized for their service to the Parkinson‘s community. The 2019 honorees are highlighted below. Social … teach newer advocates in Maryland the ins and outs of how Congress works. Milly Kondracke Award for Outstanding …
-
Will You Be My Buddy? Finding Mentors, Friends and Parkinson's Support
June 16, 2021
… It’s no exaggeration to say that social connection and building community are essential to living well … And we’ll talk to a few users of the new network on how they found their buddies and mentors, and what it’s …
-
Michael J. Fox Foundation and Elan Commit up to $2 Million to Drive Novel Therapies for Parkinson's
October 11, 2006
… J. Fox Foundation for Parkinson’s Research (MJFF) is committing up to $2 million for research projects to drive … for Parkinson’s disease by advancing well-validated drug targets along the therapeutics development pipeline. The …
-
Advances in Parkinson’s Therapies: Five Key Areas to Watch
August 7, 2025
… As part of The Michael J. Fox Foundation’s goal to support the development of new and better Parkinson’s … to improve upon the delivery of these treatments. New oral combinations, like Crexont (approved by the FDA in August … or stop the progression of PD, as none have been approved. However, there is ample focus on this strategy in the drug …
-
First Trial Begins Testing Drug in People with GBA Mutation
February 14, 2017
… determines eligibility and is testing a potential therapy to slow or stop disease progression. "I think of this as … mutation -- may lead to build-up of alpha-synuclein. The company is testing an inhibitor of glucosylceramide, which … clumping and protect brain cells. Laboratory tests showed pre-clinical PD models with a GBA mutation treated …